Patent
This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.
1 . A method of treating a disease or condition in a mammal, wherein the disease or condition is selected from:
diabetes;
impaired glucose tolerance;
reduced insulin sensitivity:
reduced fed insulin secretion;
elevated fasted insulin secretion;
elevated body fat mass; and
elevated mesenteric fat mass;
and the method comprises:
administering to a mammal in need of such treatment Bifidobacterium animalis subsp. lactis strain 420 such that an effect of the treatment of the disease or the condition is selected from:
reducing plasma insulin;
reducing body weight gain following a high fat diet;
increasing insulin sensitivity following the high fat diet; or
reducing liver and muscle tissue inflammation following the high fat diet.
2 . The method of claim 1 , wherein: the method comprises treating the diabetes, and the diabetes is Type 2 diabetes.
3 . The method of claim 1 , wherein the mammal in need of the treatment ingests a high-fat diet.
4 . The method of claim 1 , further comprising administering metformin in combination with the Bifidobacterium animalis subsp. lactis strain 420 for reducing fasting plasma insulin.
5 . The method of claim 4 , further comprising administering polydextrose in combination with the metformin and the Bifidobacterium animalis subsp. lactis strain 420 for reducing fasting plasma glucose.
6 . The method of claim 1 , further comprising administering Lactobacillus acidophilus strain NCFM (ATCC PTA-4797) in combination with the Bifidobacterium animalis subsp. lactis strain 420 and the effect is reducing body weight gain following a high fat diet.
7 . The method of claim 1 , further comprising administering Lactobacillus acidophilus strain NCFM (ATCC PTA-4797) in combination with the Bifidobacterium animalis subsp. lactis strain 420 and the effect is reducing plasma insulin.
8 . The method of claim 1 , further comprising administering Lactobacillus acidophilus strain NCFM (ATCC PTA-4797) in combination with the Bifidobacterium animalis subsp. lactis strain 420 and the effect is reducing liver and muscle tissue inflammation following the high fat diet.
9 . The method of claim 1 , wherein the step of administering comprises: providing an effective amount of the Bifidobacterium animalis subsp. lactis strain 420 at a dosage ranging from 10 6 Colony-Forming Units to 10 12 Colony-Forming Units of the Bifidobacterium animalis subsp. lactis strain 420 per dose.